Quick Verdict — Who Wins?
Retatrutide wins on every efficacy metric: most weight lost, fastest loss, no plateau, best liver health data, and metabolic rate elevation that the other two compounds can't match. The only areas where semaglutide and tirzepatide lead: FDA approval status and years of real-world post-marketing data.
The Core Difference: How Many Receptors
Every other comparison flows directly from this one fact:
Single agonist
Dual agonist
Triple agonist
The progression from 1 receptor to 2 to 3 isn't linear — it's synergistic. Adding GIP to GLP-1 improved results from ~15% to ~21%. Adding Glucagon to GIP+GLP-1 pushed from ~21% to 24.2% at a shorter timeframe, with no plateau. Each additional receptor target multiplies rather than simply adds to the effect.
The Master Comparison Table
Every metric that matters for research comparison, side-by-side:
Weight Loss — The Visual Comparison
Sources: STEP-1 (semaglutide), SURMOUNT-1 (tirzepatide), NEJM Phase 2 (retatrutide). Not direct head-to-head trials.
Metabolic Outcomes Beyond Weight Loss
The greatest difference between Retatrutide and its predecessors isn't just the headline weight loss number — it's what happens to the rest of the body's metabolic markers simultaneously:
Liver Fat Reduction
Triglycerides
Waist Circumference
Side Effects — What to Expect
All three compounds are GLP-1 receptor agonists, and all three share the same class-level side effect profile driven by GLP-1 activation in the GI tract:
- Nausea: The most common side effect across all three. Dose-dependent and typically strongest during the escalation phase. Usually resolves or becomes manageable after several weeks.
- Vomiting: Less common than nausea, typically mild, resolves with dose stabilization.
- Constipation or diarrhea: Common GI effects, usually transient.
- Decreased appetite: The intended therapeutic mechanism, but can be pronounced enough to feel like a side effect.
Retatrutide's Phase 2 showed a GI side effect profile broadly comparable to semaglutide and tirzepatide at equivalent weight loss doses. The addition of glucagon receptor agonism did not introduce new categories of side effects beyond those expected from GLP-1 class drugs.
All three compounds use a dose escalation schedule specifically to minimize GI side effects by allowing the body to adapt at lower doses before reaching the target maintenance dose.
Research Use Cases — Which to Choose?
Choose Semaglutide For:
- Pure GLP-1 mechanism isolation studies
- Cardiovascular outcomes research (extensive SELECT trial data)
- Neurological/addiction research (extensive published literature)
- Comparison control arm for newer compounds
- Research requiring maximum published literature depth
Choose Tirzepatide For:
- Dual GIP/GLP-1 mechanism studies
- T2D research with established approval framework
- Head-to-head comparison vs semaglutide protocols
- Studies where glucagon confounding is undesirable
- Research building on SURMOUNT trial framework
Choose Retatrutide For:
- Maximum weight loss pharmacology research
- Glucagon receptor agonism studies
- NASH/NAFLD hepatic fat research
- Resting energy expenditure and thermogenesis studies
- Multi-pathway obesity mechanism research
- Comparing triple vs dual vs single agonist outcomes
Where to Buy Retatrutide for Research
Research-grade Retatrutide is available from QSC Peptides at qscpeptide.com via ShopReta.com — ≥99% purity, COA on every order, free shipping, domestic warehouses in USA, EU, UK, Australia, and Canada. Prices from $0.76/mg on bulk kits.